Neuropathic Pain Market Size, Development Status, Top Manufacturers, and Forecasts

SDKI Inc. published a new report on the neuropathic pain market. This study includes the statistical and analytical approaches needed to grow the neuropathic pain market. The key industry insights provided in the report provide readers with better ideas about market overviews regarding existing market scenarios. In addition, the report contains a detailed discussion of current and future market trends related to market growth.

Report sample URL
https://www.sdki.jp/sample-request-104018

The global neuropathic pain market is expected to grow at a CAGR of 6.1% during the 2022-2030 forecast period.

The increased incidence of diabetes and cancer is a major driver of the growth of the neuropathic pain market worldwide. Diabetes is the most common indication for neuropathic pain, followed by cancer. According to the International Diabetes Federation, more than 420 million adults will have diabetes in 2016, an increase of 8.4% and is expected to reach 625 million by 2040. I am. In addition, the increase in the elderly population is expected to contribute to the growth of the market. In addition, increasing patient awareness of the treatment of neuropathic pain, increasing demand for generic medicines, and the introduction of new products for the treatment of neuropathic pain will drive the growth of the neuropathic pain market. Is a factor. In addition, strong medical infrastructure and established reimbursement create growth opportunities in this market over the next few years.

However, the serious side effects of opioids and steroids, as well as rising prices for branded drugs, can hinder the growth of the global neuropathic pain market.

Market segment

Neuropathic pain The market is by type (phantom limb pain, trigeminal neuralgia, postherpetic neuralgia, post-traumatic neuropathy), indication (spinal stenosis, and diabetic neuropathy), and diagnosis. (Imaging and blood tests), by treatment (type of medication, type of NSAID, type of antidepressant, and multidisciplinary treatment), by distribution channel (retail and drug stores, and online pharmacies), end users It is divided by distinction (hospital, clinic) and region. These segments are further subsegmented based on various factors and consist of some additional information about the market, such as the combined annual growth rate of each segment and subsegment, the market value and volume of the valuation period.

Area overview

The North American region holds the largest market share and is expected to dominate the neuropathic pain market during the forecast period. This is mainly due to the strong distribution network and the presence of advanced medical infrastructure and key players in the markets in the region. In addition, the growing elderly population, which leads to many disabilities and illnesses, is another factor driving market growth in North America. The European market, on the other hand, is estimated to be the second largest during the forecast period. This is due to the increasing number of cancer patients in the area. In addition, the Asia-Pacific region is estimated to grow at a beneficial rate due to the increasing incidence of diabetes in countries such as China and India.

These regional segments are North America (US and Canada); Asia Pacific (China, India, Japan, South Korea, Indonesia, Malaysia, Australia, New Zealand, and other Asia Pacific); Latin America (Brazil, Mexico, Argentina, and other Latin). USA); Middle East and Africa (Israel, GCC [Saudi Arabia, Arab Emirates, Bahrain, Kuwait, Qatar, Oman], North Africa, South Africa, and other Middle East and Africa) and Europe (UK, Germany, France, Italy, Spain) , Hungary, Belgium, Netherlands, Luxemburg, NORDIC, Poland, Turkey, Russia and other Europe) and more.

Major key players on the market

Key players in the neuropathy pain market include Johnson & Johnson Services Inc., Pfizer Inc., Eli Lily and Company, GlaxoSmithKline PLC, Bristol-Myers Squibb and Company, Sanofi SA, Biogen Idec Inc., Baxter Healthcare Corporation. , Depomed Inc. and so on. The study includes a detailed competitive analysis, corporate profile, recent developments, and key market strategies for these major companies in the neuropathic pain market.

Details of the survey report
https://www.sdki.jp/reports/neuropathic-pain-market/104018

Contact Us

Hina Miyazu
15/F Cerulean Tower, 26-1 Sakuragaoka-cho
Tokyo, Shibuya-ku, Japan
+ 81345720790
sales@sdki.jp

SDKI Inc. Company Profile

SDKI Inc.'s goal is market scenarios in various countries such as Japan, China, the United States, Canada, the United Kingdom, and Germany. Is to clarify. We also focus on providing reliable research insights to clients around the world, including growth indicators, challenges, trends and competitive environments, through a diverse network of research analysts and consultants. With SDKI gaining trust and a customer base in more than 30 countries, SDKI is even more focused on expanding its foothold in other pristine economies.

This release was published on openPR.